2017
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 81. PMID: 29037255, PMCID: PMC5644103, DOI: 10.1186/s40425-017-0285-7.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerIDO1 expressionBreast cancerIndependent negative prognostic markerB cell infiltrationImmune suppressive pathwaysAdvanced solid tumorsTumor-infiltrating lymphocytesT cell responsesClinico-pathological featuresClinico-pathological characteristicsProportional hazards modelNegative prognostic markerDegradation of tryptophanMann-Whitney testFoxp3 levelsIDO1 blockadeIDO1 levelsEffector CD4Durable responsesOverall survivalImmune toleranceMultivariable analysisPrognostic marker
2014
Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
Velcheti V, Schalper K, Venur V. Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. Journal Of Receptor Ligand And Channel Research 2014, Volume 8: 1-7. DOI: 10.2147/jrlcr.s39986.Peer-Reviewed Original ResearchPD-1Tumor typesImmune checkpoint inhibitorsDeath-1 (PD-1) pathwayPD-1 ligandsDeath-1/Death 1 ligandDurable antitumor activityImmune checkpoint pathwaysAntigen-presenting cellsPromising anticancer therapeutic strategyPD-L1Immune toleranceInvestigational agentsImmune microenvironmentClinical activityT cellsAnticancer therapeutic strategiesTherapeutic strategiesTherapeutic targetClinical developmentTumor cellsMonoclonal antibodiesAntitumor activityTherapeutic antibodies